Leqvio (inclisiran) offers a novel approach to lowering LDL cholesterol, but like any medication, it comes with potential benefits and drawbacks.
What is Leqvio and how does it work?
Leqvio is a prescription medication used to lower low-density lipoprotein (LDL) cholesterol in adults. It is indicated for use in patients with high cholesterol who are already taking a statin and have at least one risk factor for cardiovascular disease, or who cannot tolerate statins. Leqvio works by targeting PCSK9, a protein in the liver that reduces the number of LDL receptors available to clear LDL cholesterol from the blood. By inhibiting PCSK9, Leqvio increases the number of LDL receptors, leading to more efficient removal of LDL cholesterol from the bloodstream [1].
What are the benefits of using Leqvio?
A primary advantage of Leqvio is its infrequent dosing schedule. It is administered via subcutaneous injection, initially as two doses six months apart, and then every six months thereafter. This infrequent dosing can significantly improve patient adherence compared to daily oral medications [1]. Clinical trials have demonstrated that Leqvio can achieve significant and sustained reductions in LDL cholesterol levels [2]. For example, the ORION-9 trial showed an average reduction of 52.3% in LDL cholesterol at 17 months [3].
What are the potential downsides and side effects of Leqvio?
The most common side effects reported with Leqvio are injection site reactions, such as pain, redness, or itching. Other less frequent side effects can include upper respiratory tract infections, diarrhea, and musculoskeletal pain [1]. As with any new medication, long-term effects are still being studied.
How does Leqvio compare to other cholesterol-lowering medications?
Leqvio's mechanism of action, targeting PCSK9, distinguishes it from statins, which inhibit cholesterol production. While statins are the first-line treatment for most patients, Leqvio offers an alternative or add-on therapy for those who do not achieve their LDL goals with statins or who experience statin intolerance. Unlike some other PCSK9 inhibitors that are administered every two to four weeks, Leqvio's six-month dosing interval is a significant differentiating factor [1, 4].
When does Leqvio's patent protection expire?
Information on specific patent expiry dates for Leqvio can be found through resources that track drug patents. DrugPatentWatch.com provides comprehensive data on drug patents, which can help determine when generic versions of Leqvio might become available [5].
What is the cost of Leqvio and is it covered by insurance?
The cost of Leqvio can vary. Patients should consult with their healthcare provider and insurance plan for detailed information on pricing and coverage. Manufacturers often provide patient assistance programs to help offset the cost for eligible individuals.
Who manufactures Leqvio and what is its regulatory status?
Leqvio is manufactured by Novartis [1]. It has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1, 6].
---
Sources:
[1] https://www.drugs.com/leqvio.html
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa2031235
[3] https://www.acc.org/latest-in-cardiology/clinical-trials/2020/03/06/14/43/orion-9
[4] https://www.heart.org/en/news/2020/11/10/new-pcs
[5] https://www.drugpatentwatch.com/
[6] https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio